MYC and cancer: First, it presents the first evidence that the NLS1–Basic–NLS2 region of c‐Myc is a druggable target by a small molecule, which turns the “undruggable” target c‐Myc into a druggable target, thus paving the way for the design of c‐Myc small inhibitors that direct pharmacological inhibition of c‐Myc‐positive cancers.